All In Biotech

Drug Trial Radar · NCT06254950

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 213 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

213

Actual

Start

Mar 29, 2024

Primary completion

Jul 14, 2026

Study completion Aug 4, 2027

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Feb 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks). During the study, participants will visit their study clinic several times.

Conditions

  • Ulcerative Colitis

Interventions

  • TAK-279Drug

    TAK-279 capsules.

  • PlaceboDrug

    TAK-279 placebo-matching capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Clinical Remission at Week 12 Based on Modified Mayo Score (mMS)Time frame: Week 12

Locations

141 sites in 22 countries. Site status is shown where the registry gives one.

  • GastroIntestinal BioSciences

    Los Angeles, California

  • United Medical Doctors

    Murrieta, California

  • West Central Gastroenterology, LLP, d/b/a/ Gastro Florida

    Clearwater, Florida

  • Auzmer Research

    Lakeland, Florida

  • GI PROS, Inc.

    Naples, Florida

  • USF Health Morsani Center for Advanced Healthcare

    Tampa, Florida

  • Emory University Hospital, The Emory Clinic

    Atlanta, Georgia

  • Atlanta Center For Gastroenterology, P.C.

    Decatur, Georgia

  • University Of Louisville

    Louisville, Kentucky

  • Woodholme Gastroenterology Associates

    Glen Burnie, Maryland

  • Las Vegas Medical Research

    Las Vegas, Nevada

  • University Gastroenterology

    Providence, Rhode Island

  • Gastroenterology Associates, PA

    Greenville, South Carolina

  • Novel Research, LLC

    Bellaire, Texas

  • Tyler Research Institute, LLC

    Tyler, Texas

  • University of Washington Medical Center

    Seattle, Washington

  • Harry Perkins Medical Research Institute Fiona Stanley Hospital

    Murdoch, Australia

  • Concord Repatriation General Hospital

    Sydney, New South Wales, Australia

  • Mater Cancer Care Centre-Mater Health Services

    South Brisbane, Queensland, Australia

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia

  • The Queen Elizabeth Hospital

    Woodville, South Australia, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Western Health/Footscray Hospital

    Melbourne, Victoria, Australia

  • Sir Charles Gairdner Hospital Lung Institute Of Western Australia

    Nedlands, Western Australia, Australia

  • Royal Perth Hospital

    Perth, Western Australia, Australia

  • Universitair Ziekenhuis Leuven

    Leuven, Belgium

  • Hopital Universitaire de Bruxelles/ Academisch Ziekenhuis Burssel

    Brussels, Anderlecht / Region Capitale de Bruxelles/ Brussel, Belgium

  • UMBAL Kaspela

    Plovdiv, Bulgaria

  • Pecs University Clinical Center Mohacs Hospital

    Sofia, Bulgaria

  • Acibadem City clinic Tokuda hospital

    Sofia, Bulgaria

  • Diagnostic-Consultative Center Aleksandrovska EOOD

    Sofia, Bulgaria

  • University Hospital Tsaritsa Yoanna - Isul (University Hospital Queen Giovanna)

    Sofia, Bulgaria

  • University Hospital City Clinic Cancer Center

    Sofia, Bulgaria

  • Heritage Medical Research Clinic - University Of Calgary

    Calgary, Alberta, Canada

  • Fraser Clinical Trials

    New Westminster, British Columbia, Canada

  • London Health Sciences Centre - University Hospital

    London, Ontario, Canada

  • London Health Sciences Centre - Victoria Hospital

    London, Ontario, Canada

  • Centre Hospitalier de l'Universite de Montreal

    Montreal, Quebec, Canada

  • The Research Institute of the McGill University Health Center

    Montreal, Quebec, Canada

  • Zhejiang University School of Medicine - Sir Run Run Shaw Hospital (SRRSH)

    Hangzhou, China

Showing 40 of 141 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.